IN8bio, Inc. Common Stock (INAB) Stock Price
INABStock
$1.17−47.79%52W
Market Cap$11.53M
P/E—
PEG Ratio—
Div yield—
Beta0.38
INAB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-41.01%
Price vs S&P 500 (4W)3.25%
VGM Score30.99
INAB Earnings Surprise History
Q2 25-1.24est. -1.80
Q3 25-0.85est. -1.25
Q4 25-0.45est. -0.47
Q1 26-0.26est. -0.69
Q2 26-0.25est. -0.37
INAB Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.10
4.10
4.10
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INABIN8bio, Inc. Common Stock | — | — | D | $1.17 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About IN8bio, Inc. Common Stock
IN8bio Inc is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and liquid tumors using allogeneic, autologous, and engineered cell approaches. Lead programs include INB-400 for glioblastoma and INB-100 for high-risk leukemias, with additional candidates in earlier development stages.